Test, Hepatitis B (B Core, Be Antigen, Be Antibody, B Core Igm)
Basic Information
- Device Name
- Test, Hepatitis B (B Core, Be Antigen, Be Antibody, B Core Igm)
- Trade Name
- LIAISON XL MUREX Anti-HBc, LIAISON MUREX Control Anti-HBc
- PMA Number
- P180038
- Device Class
- FDA Class 3
- Product Code
- LOM
- Generic Name
- Test, hepatitis b (b core, be antigen, be antibody, b core igm)
- Medical Specialty
- Unknown
- Advisory Committee
- Microbiology
- Decision
- Approved
- Decision Code
- APPR
- Decision Date
- January 2, 2020
- Date Received
- September 26, 2018
- Expedited Review
- N
- Docket Number
- 20M-0107
Advisory Committee Statement
Approval for the LIAISON XL MUREX Anti-HBc assay is an in vitro chemiluminescent immunoassay (CLIA) for the qualitative detection of IgG and IgM (total) antibodies to hepatitis B core antigen (anti-HBc) in human adult and pediatric serum and plasma (lithium and sodium heparin, sodium citrate and K2 EDTA) including separator tubes, on the LIAISON XL Analyzer. Assay results in conjunction with other laboratory results and clinical information may be used as an aid in the diagnosis of hepatitis B virus (HBV) infection in patients with symptoms of hepatitis or who may be at risk for HBV infection. The assay is not intended for use in screening blood, plasma or tissue donors. The LIAISON XL MUREX Control Anti-HBc (negative and positive) is intended for use as assayed quality control samples to monitor the performance of the LIAISON XL MUREX Anti-HBc assay. The performance characteristics of LIAISON XL MUREX Control Anti-HBc have not been established for any other assays or instrument platforms.
Classifications
This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.
| Product Code | Device Name | Device Class | Medical Specialty |
|---|---|---|---|
| LOM | Test, Hepatitis B (B Core, Be Antigen, Be Antibody, B Core Igm) | FDA class 3 | Unknown |